Replies to post #31920 on Intellipharmaceutics International Inc. (IPCI)

[bluelucky]

Agreed on the increased split. If I remember correctly it was double.

We need more clarity on the numbers for sure

[doogdilinger]

I am not sure I understand how the company is planning to attain a cash flow positive status given very low sales.

Sadly I agree swe77. If the disappointing MNK/SeroquelXR sales results continue to be the norm...IPCI's gonna be lucky to generate a deeply disappointing total of $1M in fiscal 2018 revenue from that deal...which is soooooooo far below all our earlier expectations and that of the analysts, it crushes any potential enthusiasm for the still pending Pristiq and Lamictal FDA approvals...knowing they're both probably going to be suffering the same fate SeroquelXR has(so far anyways).

A few people have said that they expect MNK to capture more market share at some point next year whenever they can put in more bids. So perhaps that will have a positive impact on the SeroquelXR revenue by mid-point next year despite the fact that MNK continues trying to sell their generics division.

It's bad enough that all the unforeseen things that could go wrong on FocalinXR and everything else over the past 4 years did go wrong...but talk about terrible timing on IPCI's 3 ANDA deals with MNK...it's like for 4 years running now everything that can possibly go wrong has.

So I'm hoping that over the next 4 years everything that can go right starts happening for IPCI...the yin to the yang so to speak...and we finally get some major positivity and enthusiasm flowing again for Dr. Odidi's science!